Background-Emerging evidence has suggested a contribution of bone marrow (BM) cells to lymphatic vessel formation; however, the exact phenotype of the cells with lymphatic endothelial progenitor cell function has yet to be identified. Here, we investigate the identity of BM-derived lymphatic endothelial progenitor cells and their role in lymphatic neovascularization. Methods and Results-Culture of BM-mononuclear cells in the presence of vascular endothelial growth factors A and C and endothelial growth factor resulted in expression of lymphatic endothelial cell markers. Among these cells, podoplanin ϩ cells were isolated by magnetic-activated cell sorting and characterized by fluorescence-activated cell sorter analysis and immunocytochemistry. These podoplanin ϩ cells highly express markers for lymphatic endothelial cells, hematopoietic lineages, and stem/progenitor cells; on further cultivation, they generate lymphatic endothelial cells. We further confirmed that podoplanin ϩ cells exist in small numbers in BM and peripheral blood of normal mice but are significantly (15-fold) augmented on lymphangiogenic stimuli such as tumor implantation. Next, to evaluate the potential of podoplanin ϩ cells for the formation of new lymphatic vessels in vivo, we injected culture-isolated or freshly isolated BM-derived podoplanin ϩ cells into wound and tumor models. Immunohistochemistry demonstrated that the injected cells were incorporated into the lymphatic vasculature, displayed lymphatic endothelial cell phenotypes, and increased lymphatic vascular density in tissues, suggesting lymphvasculogenesis. Podoplanin ϩ cells also expressed high levels of lymphangiogenic cytokines and increased proliferation of lymphatic endothelial cells during coculture, suggesting a lymphangiogenic or paracrine role. Conclusions-Our results provide compelling evidence that BM-derived podoplanin ϩ cells, a previously unrecognized cell type, function as lymphatic endothelial progenitor cells and participate in postnatal lymphatic neovascularization through both lymphvasculogenesis and lymphangiogenesis. (Circulation.
L ymphatic vessels play an important role in the pathogenesis of diseases such as lymphedema and tumors, 1, 2 and an understanding of lymphatic biology is crucial to develop strategies to prevent or treat these diseases. Investigation of lymphatic vascular growth was made possible by the discovery of specific markers for lymphatic endothelial cells (LECs). The establishment of the lymphatic vasculature during mouse embryogenesis begins with expression of homeobox transcriptional factor PROX-1 in a subset of the venous endothelial cells of the cardinal vein 3 that express vascular endothelial growth factor (VEGF) receptor (VEGFR)-3 4 and LYVE-1. 5 Subsequently, the PROX-1-expressing (PROX-1 ϩ ) cells migrate out to form the primary lymphatic plexus, which undergoes further remodeling to form a mature network of LECs that express other LEC markers such as podoplanin (pod). 6, 7 Pod is a 38-kDa integral membrane mucoprotein that is expressed predominantly in the endothelium of lymphatic capillaries. 7 Mice deficient in pod die at birth as a result of respiratory failure accompanied by malfunctioning lymphatic, but not blood, vessels with impaired lymphatic transport and congenital lymphedema. 8 
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The generation of lymphatic vessels in adults was previously believed to be achieved exclusively by a process called lymphangiogenesis, the formation of new lymphatic vessels from preexisting lymphatic vasculature. 9 -13 However, emerging evidence has suggested that lymphvasculogenesis may also occur through putative progenitor cells for LECs. Studies have shown that bone marrow (BM) contains cells with the potential to generate LECs. 14 -17 An early study reported that human fetal liver-derived, nonadherent CD34 ϩ CD133 ϩ VEGFR-3 ϩ cells, when cultured, became adherent and expressed LYVE-1 or pod, implying a role for these cells as common blood vascular and lymphatic endothelial progenitor cells (LEPCs). 14 Using a chimeric mouse model in which BM of wild-type mice was reconstituted by BM transplantation from donor green fluorescent protein (GFP) mice, Religa and colleagues 16 subsequently showed that BM-derived cells were incorporated into newly formed lymphatic vessels in corneas. Maruyama and colleagues demonstrated incorporation of mouse GFP-BM cells into lymphatic vessels in inflamed corneas. 15 This study showed that tissue-resident CD11b ϩ macrophages, presumably derived from BM, were incorporated into inflammation-induced lymphatics in the cornea. Kerjaschki et al 17 demonstrated the presence of male recipient-derived LECs in the lymphatic vessels in kidneys transplanted from female donors. Together, these studies support the idea that a certain population of BM cells, likely of monocyte-macrophage lineages, can give rise to LECs in the foci of new lymphatic vessel formation (lymphatic neovascularization) in various pathological conditions. However, no studies have clearly addressed the exact identity of BM-derived LEPCs in adults and tested their potential for lymphatic neovascularization by external implantation of isolated LEPCs.
In this study, we show for the first time that pod ϩ CD11b ϩ cells exist in adult BM and can function as LEPCs. We also demonstrate that these cells contribute to lymphatic neovascularization through dual lymphvasculogenic and lymphangiogenic roles.
Methods
All protocols for animal experiments were approved by the Institutional Animal Care and Use committees of Emory University.
Culture of BM Mononuclear Cells
Mouse BM mononuclear cells (MNCs) fractionated by density gradient centrifugation with Histopaque-1083 (Sigma, St Louis, Mo) were seeded onto 100-mm culture dishes coated with rat vitronectin. To optimize culture conditions to generate LEPCs, 4 different combinations of media were used (Table I in the online-only Data Supplement). To differentiate sorted putative LEPCs derived from cultured BM-MNCs into LECs, the cells were maintained in endothelial cell basal medium-2 (EBM-2) supplemented with cytokine cocktail (SingleQuots; Lonza (San Diego, Calif) for 7 days.
LEC Proliferation Assay
The sorted pod ϩ and pod Ϫ cells (2.5ϫ10 3 ) from BM-MNCs cultured for 4 days were mixed with human dermal LECs (1.5ϫ10 4 ; Cambrex, East Rutherford, NJ) that were prelabeled with CM-Dil (Invitrogen, Carlsbad, Calif), seeded onto 96-well culture plates, and cocultured in endothelial cell growth medium media with 1% FBS. Twenty-four hours later, cells were stained with Ki67 antibody and counterstained with DAPI. Cells positive for Dil, Ki67, and DAPI were counted.
Mouse Cornea Model
A micropocket was created, followed by implantation of a micropellet containing VEGF-C and fibroblast growth factor-2. 18 Subsequently, CM-Dil-labeled pod ϩ cells cultured for 4 days were injected into the surrounding area in the cornea. Eyeballs were isolated 7 days later and subjected to immunohistochemistry.
Skin and Ear Wound Models
After creating full-thickness excisional skin wounds on the backs or ears of the mice, we injected pod ϩ cells labeled with DiI or derived from GFP mice into the wound bed around the wound. Seven days later, the wound tissues, including a perimeter of 1 to 2 mm of normal skin tissue, were harvested for immunohistochemistry.
Mouse Tumor (Melanoma) Model
Tumor cells (B16-F1 melanoma cell line) were subcutaneously injected into the middle dorsum of C57BL/6 mice. Seven days later, Dil-labeled pod ϩ cells isolated from cultured BM-MNCs were injected into the tumor vicinity, and the mice were euthanized 7 days later for immunohistochemistry.
Measurement of Lymphatic Capillary Density
After implantation of tumors (melanomas) and injection of pod ϩ cells, pod Ϫ cells, or the same volume of PBS as described above, tumors and surrounding peritumoral tissues with skin were harvested and subjected to immunohistochemistry with a VEGFR-3 antibody. 19 Lymphatic capillary density was calculated from at least 10 randomly selected fields.
Statistical Analysis
All results are presented as meanϮSE. Statistical analyses were performed with the Mann-Whitney U test for comparisons between 2 groups and the Kruskal-Wallis ANOVA test for Ͼ2 groups. Values of PՅ0.05 were considered to denote statistical significance. Details on the above and other methods can be found in the online-only Data Supplement.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results

BM-MNCs Cultured Under Defined Conditions Express LEC Markers
To explore whether BM-MNCs include potential LEPCs, we first examined LEC marker expression in freshly isolated BM-MNCs of FVB mice by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). Uncultured BMMNCs expressed Cd31 and Lyve1 but not Prox1, Vegfr3, or pod ( Figure 1A) . Next, to investigate whether culture of BM-MNCs under defined conditions can induce LEC gene expression, we cultured BM-MNCs in EBM-2 supplemented with VEGF-A, VEGF-C, and epidermal growth factor (EGF) individually or in various combinations (Table I in the online-only Data Supplement). We selected VEGF-A and VEGF-C because of their known role as lymphatic growth factors 11, 20 and EGF because of its role in cell proliferation. 21 Expression of Prox1 and Vegfr3 emerged at day 1, reached a peak at day 4, and decreased but continued until day 7. Pod expression went up from day 1 and was sustained until day 10; Cd31 and Lyve1 expression decreased over the 4 days ( Figure 1A ). Another lymphatic marker, Foxc2, was also expressed in the VEGF-A, VEGF-C, and EGF (ACE) condition with a peak at day 4 (data not shown). From these experiments, we found that cultivation of BM-MNCs with lymphangiogenic factors can generate LEC-like cells. We further found that 4-day culture under the ACE condition was optimal for generating LEC-like cells because all the LEC markers were significantly expressed whereas expression of a pan-vascular endothelial cell marker, Cd31, was significantly reduced at day 4. Immunocytochemistry and fluorescence-ac-tivated cell sorter (FACS) analysis also confirmed the qRT-PCR results ( Figure 1B and 1J) . FACS analyses showed a significant increase in pod ϩ and VEGFR-3 ϩ cells and similar levels of LYVE-1 ϩ cells in cultured BM-MNCs compared with the freshly isolated BM-MNCs ( Figure 1J ). The expression levels of LEC markers in the pod ϩ cells were similar to those of mouse LECs isolated from a mouse EC line, SVEC4 -10ϩ ( Figure I in the online-only Data Supplement). Taken together, these results indicate that culture of BM-MNCs under the ACE condition can generate cells expressing LEC markers. We therefore used this culture condition for the following experiments.
Pod
؉ Cells Isolated From Cultured BM-MNCs Express LEC Markers, Hematopoietic and Stem/Progenitor Cell Markers, and Lymphangiogenic Cytokines
Because these cultured cells were still heterogeneous, we next sought to enrich cells with the LEC phenotype using a cell sorting strategy. Among the 3 representative LEC surface markers, LYVE-1, VEGFR-3, and pod, we selected pod on the basis of the qRT-PCR data ( Figure 1A ), which showed pod expression to be the most stable from day 4 on. Pod has been implicated in proper patterning of lymphatic vessels and lymphedema. 7, 8 Accordingly, we isolated pod ϩ or pod Ϫ cells from the cultured BM-MNCs at day 4 by a magneticactivated cell sorting and examined the LEC markers. qRT-PCR analysis demonstrated augmented expression of Prox1 (3.7-fold), Lyve1 (3.0-fold), and pod (6.0-fold) in the pod more highly in pod ϩ cells than pod Ϫ cells, implying more potent paracrine lymphangiogenic activity of pod ϩ cells ( Figure 2B ) 2, 23, 24 Next, we examined the progenitor character of pod ϩ cells. FACS analysis showed that the hematopoietic stem cell markers Sca-1, c-KIT, and FLK-1 were expressed in 17.8Ϯ3.4%, 13.6Ϯ2.4%, and 8.6Ϯ0.9% of the pod ϩ cells, respectively ( Figure 2C ). In contrast, pod Ϫ cells expressed virtually no hematopoietic stem cell markers. More than 99% of cultured pod ϩ cells expressed CD45 ( Figure 2D ), indicating that these pod ϩ cells are hematopoietic in origin and are not contaminating preexisting LECs from BM. Importantly, when further cultured for 7 days in conventional LEC culture media, which is EBM-2 supplemented with SingleQuots (complete EGM), 25 the pod ϩ cells maintained expression of pod and LYVE-1, whereas pod Ϫ cells hardly expressed these markers ( Figure 2E ). We also found that the pod ϩ cells have multilineage differentiation potential, as demonstrated by expression of markers of blood endothelial cells, smooth muscle cells, and fibroblasts, depending on culture conditions ( Figure II in the online-only Data Supplement). Taken together, these findings indicate that pod ϩ cells isolated from cultured BM-MNCs are enriched with LEC markers and lymphangiogenic cytokines, are hematopoietic in origin, possess stem/progenitor cell characteristics, and differentiate into LECs when further cultured, suggestive of putative LEPCs.
Culture-Isolated Pod ؉ Cells Contribute to Lymphatic Vessel Formation in Animal Models
Next, we sought to determine the lymphatic neovascularization potential of these pod ϩ cells. We thus injected pod ϩ cells into 4 different animal models that are well known to induce lymphatic vessel formation: a corneal micropocket model 15 ( Figure 3A ), ear and skin wound models 26 ( Figure 3B , 3D, and 3E), and a tumor (melanoma) model 27 ( Figure 3C ). Culture-isolated pod ϩ cells prelabeled with DiI, a red fluorescent dye used for cell tracking, were injected into the margin of the cornea (cornea model) or into the subcutaneous tissues (wound models or tumor model). The tissues were harvested 7 days later and subjected to immunohistochemistry. Three-dimensional reconstruction of the confocal microscopic images demonstrated that pod ϩ cells were clearly incorporated into lymphatic vessels and colocalized with cells expressing LEC markers in tissues harvested from all 4 models ( Figure 3A through 3C and Movie I in the online-only Data Supplement). The percentage of the LYVE-1 ϩ lymphatic vessels containing Dil ϩ cells was Ϸ5.2Ϯ2.1% in the cornea, 5.5Ϯ2.5% in wound models, and 8.5Ϯ3.7% in the tumor model. Of note, the Z-stacked, 3-dimensional images of Figure 3C (tumor model) unequivocally showed that pod ϩ cells were incorporated into lymphatic vessels, exhibited a LEC marker, and had single nuclei, suggesting lymphvascu- 
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Podoplanin ؉ Cells for Lymphatic Neovascularizationlogenesis from the injected pod ϩ cells. In addition, in vivo video-rate laser scanning microscopy demonstrated incorporation and colocalization of the injected pod ϩ cells into LYVE-1 ϩ lymphatic vessels at multiple sites in the ear wound ( Figure 3D ) and cornea (data not shown) models. Immunohistochemistry further confirmed the incorporation of the injected cells into pod-expressing vessels, which displayed typical lymphatic vessel morphology ( Figure III in the online-only Data Supplement). To complement these results with Dil-labeled pod ϩ cells, we performed another experiment in which pod ϩ cells culture-isolated from GFP mice were injected into a skin wound model ( Figure 3E and Movie 2 in the online-only Data Supplement). Confocal microscopic imaging revealed that GFP ϩ cells were incorporated into lymphatic vessels and expressed LYVE-1.
We also found that a larger portion of the injected cells were localized in close proximity to the lymphatic vasculature in the ear wound, tumor, and cornea models ( Figures 3D   Figure 4 . Lymphangiogenic characteristics of pod ϩ cells. A, Pod ϩ cells sorted from BM-MNCs cultured for 4 days labeled with Dil were injected into the periphery of tumors in mice that had been injected with melanoma cells 7 days before. Seven days after cell implantation, tumor and peritumoral tissues, including skin, were harvested and underwent immunostaining for LYVE-1 (green). Arrows indicate engraftment of pod ϩ cells in close proximity to lymphatic vessels. Representative images from Ͼ2 independent experiments are shown (nϭ3 per experiment). DAPI is blue. Scale barϭ20 m. B, The peritumoral tissues that were injected with pod ϩ cells, pod Ϫ cells, or the same volume of PBS as in the procedure described above were harvested 7 days later and subjected to immunohistochemistry with a VEGFR-3 antibody. Representative images from at least 2 independent experiments are shown (nϭ2 per group). Magnification ϫ4. C, The number of VEGFR-3 ϩ vessels in peritumoral tissues was higher in mice implanted with pod ϩ cells than pod Ϫ cells or PBS. The indicated values were calculated from 2 independent experiments (B) using Ͼ10 randomly selected fields (**PϽ0.01, *PϽ0.05). D, The pod ϩ and pod Ϫ cells from BM-MNCs cultured for 4 days or PBS were mixed with Dil-labeled human dermal LECs (hDLEC; red), cultured for 24 hours, and stained for Ki67 (green). DAPI is blue. The cells positive for Dil, Ki67, and DAPI (white arrowheads) were counted. Representative images from 3 independent experiments are shown. Scale barϭ20 m. E, Human dermal LECs cocultured with pod ϩ cells exhibited a higher rate of Ki67 ϩ cells compared with controls, suggesting a lymphangiogenic role of pod ϩ cells on surrounding LECs. The indicated values are the averages calculated from 14 randomly selected fields of each group of 3 independent experiments (**PϽ0.01, *PϽ0.05). F, Tissues from mice injected with pod ϩ or pod Ϫ cells were subjected to qRT-PCR analyses. Graphs from 3 independent experiments are shown (*PϽ0.05; nϭ3 per group).
and 4A and Figure IV in the online-only Data Supplement), suggesting their lymphangiogenic role. To determine the overall lymphatic neovascularization potential of pod ϩ cells, we measured lymphatic vascular density in peritumoral tissues and found that pod ϩ cell-injected tissues showed significantly higher lymphatic vascular density than PBS-or pod Ϫ cell-injected tissues ( Figure 4B and 4C) . To further explore their lymphangiogenic role, we cocultured pod ϩ cells with DiI-labeled human dermal LECs and determined the proliferation of LECs by Ki67 staining. The number of Ki67-positive LECs was Ͼ2-fold higher in the pod ϩ cellcocultured LECs than PBS-added or pod Ϫ cell-cocultured LECs ( Figure 4D and 4E ). In agreement with these data, lymphangiogenic cytokines in tissues measured at day 7 after injection of 2ϫ10 6 pod ϩ cells in the skin wound model were significantly increased in the pod ϩ cellinjected mice compared with PBS-or pod Ϫ cell-injected tissues ( Figure 4F ). From these in vitro and in vivo studies, we concluded that culture-isolated pod ϩ cells have dual lymphvasculogenic and lymphangiogenic roles and augment lymphatic neovascularization. Figure 1J ), we hypothesized that if these cells function as LEPCs, the number would be increased in the BM and/or peripheral blood (PB) under conditions promoting lymphatic vascular growth. Hence, we injected B16-F1 melanoma cells 27 subcutaneously into the backs of mice and examined the number of pod ϩ cells in BM and PB 7 days later by FACS. FACS analysis showed that pod ϩ cells in BM and PB were Ͻ0.5% in healthy C57/BL6 mice but increased Ϸ15-fold both in BM and PB on the Figure 5A and 5C). Similar results were found in nude mice implanted with MDA-MB-231 human breast cancer cells (data not shown). Next, we examined the expression of VEGFR-3, LYVE-1, and c-KIT in pod ϩ cells isolated from BM and PB of normal and tumor-bearing mice to determine the progenitor and lymphatic character of the pod ϩ cells. FACS analysis of BM cells showed that among the pod ϩ population, the c-KIT ϩ or VEGFR-3
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ϩ , but not LYVE-1 ϩ , cells were more highly enriched in the tumor (melanoma)-bearing mice than in the normal mice ( Figure 5B ). The frequency of c-KIT ϩ cells in the pod ϩ population of tumor-bearing mice was 24.8Ϯ3.3%, whereas Ϸ16.3Ϯ2.0% of c-KIT ϩ cells were pod ϩ (Figure V in the online-only Data Supplement). In PB cells, among the pod ϩ population, VEGFR-3 ϩ or LYVE-1 ϩ , but not c-KIT ϩ . cells were more enriched in the tumor-bearing mice than in the normal mice. These findings suggest that during the process of lymphatic vascular growth, pod ϩ cells not only increase in number but also undergo qualitative changes into more lymphatic and progenitor-like cells, as evidenced by an increase in VEGFR-3, LYVE-1, and c-KIT, respectively. We also observed differences between BM and PB in the composition of these markers. In BM, c-KIT expression was higher in tumor mice than normal mice; in PB, however, there was no difference in c-KIT expression between the two ( Figure 5B and 5D, left) . On the other hand, there was no difference in LYVE-1 expression in BM between tumor mice and normal mice, but in PB, the expression was higher in tumor mice than normal mice ( Figure 5B and 5D, right) . In summary, among pod ϩ cells, c-KIT ϩ cells were more enriched in BM and LYVE-1 ϩ cells were more enriched in PB in tumor mice compared with normal mice. Because stem/ progenitor cells are more predominant in BM and undergo differentiation during mobilization into PB, these results imply that among pod ϩ cells, progenitor forms are more prevalent in BM, and during and after mobilization into PB, the composition of pod ϩ cells shifts to more lymphatic and less progenitor-like phenotypes. The increase in absolute percentage of VEGFR-3 ϩ cells among the pod ϩ population in PB compared with BM further supports this interpretation ( Figure 5B and 5D, middle) . Finally, to determine the lymphvasculogenic potential of freshly isolated BM pod ϩ cells in vivo, we injected the pod ϩ cells (Dil labeled) derived from BM of tumor-bearing mice into skin and ear wound models. Immunohistochemistry showed that the injected cells were incorporated into lymphatic vessels and exhibited an LEC marker ( Figure 6A and 6B) . Together, these results demonstrated that pod ϩ cells are present in BM and PB, are increased in number under lymphatic vascular growth conditions, and contribute to lymphvasculogenesis, suggesting a pathophysiological role of pod ϩ cells as LEPCs in vivo.
Pod Is a Determining Marker to Confer Lymphatic and Progenitor Cell Properties
Because previous studies documented that tissue resident CD11b ϩ macrophages express LEC markers and could contribute to lymphatic vessel formation, 15 we further explored the relationship between pod and CD11b in BM-MNCs using FACS analysis. Approximately 50% of the freshly isolated BM-MNCs expressed CD11b, but Ͻ1% expressed pod (Figure 7A, left) . In freshly isolated BM-MNCs, 85% of the pod 
CD11b
ϩ cells was increased in BM of tumor-bearing mice undergoing active lymphatic neovascularization ( Figure VI in the online-only Data Supplement). Together, these results suggest that during lymphatic activation, the frequency of BM cells expressing either pod or CD11b is increased, especially for cells expressing both pod and CD11b.
Next, to further define the phenotype of pod-or CD11b-expressing cells, we investigated the expression of other LEC markers (VEGFR-3 and LYVE1) and stem/progenitor markers (c-KIT and Sca-1) in each cell fraction ( Figure 7B ). FACS analysis showed that VEGFR-3 ϩ cells and LYVE-1 ϩ cells were present almost exclusively in the pod ϩ population, the 
ϩ cells minimally expressed pod and did not express LYVE-1, VEGFR-3, or PROX-1 ( Figure 7C through 7X) . These data indicate that almost all the stem/progenitor cells were exclusively restricted to the pod ϩ CD11b ϩ , ie, pod ϩ , cell population. As a whole, these findings suggest that pod, more than CD11b, is a determining marker to confer lymphatic and progenitor cell properties on BM cells, robustly supporting the role of pod ϩ cells as LEPCs.
Loss of Hematopoietic Properties of Pod
؉
CD11b
؉
Cells During Differentiation Into LECs
We next investigated whether the hematopoietic character of the putative LEPCs or pod Figure 8I ). To further verify these findings in vivo, we injected DiI-labeled pod ϩ CD11b ϩ cells sorted from the cultured BM-MNCs into mice with skin wounds. Figure 8J clearly shows that expression of CD45 was not detected in the pod ϩ CD11b ϩ cells incorporated into lymphatic vessels (Figure 8J ). These data indicate that pod ϩ CD11b ϩ cells lost hematopoietic properties during differentiation into LECs.
Discussion
This is the first study to demonstrate the presence of pod ϩ cells in the circulatory system and to provide evidence that these cells can function as LEPCs. Pod ϩ cells exist in BM and PB in very low amounts at steady state and increase in number under conditions that promote lymphatic vascular growth such as melanoma. 27 Pod ϩ cells are expandable by culture with lymphangiogenic growth factors. Because lymphangiogenic tumors such as melanoma or breast cancer 28 or inflammation 15, 29 induces an increase in the local concentration of lymphatic growth factors, the cell culture conditions closely mimic the local environment of these conditions. We also successfully generated LECs in vitro by further cultivation of these culture-isolated pod ϩ cells. Thus, this in vitro and in vivo evidence strongly suggests a crucial role for pod ϩ cells in lymphatic vessel formation. High expression of other LEC genes and lymphangiogenic cytokines in pod ϩ cells further supports their role in lymphatic neovascularization. The almost exclusive restriction of c-KIT, Sca-1, and FLK-1 expression to pod ϩ cells suggests their stem/progenitor cell character.
More direct evidence of lymphatic neovascularization by pod ϩ cells was provided by the cell injection studies. Both freshly isolated and cultured pod ϩ cells were not only incorporated as LECs into lymphatic vasculature (lymphvasculogenesis) but also highly localized near the lymphatic vasculature, suggestive of a paracrine or lymphangiogenic role. Although there is controversy around the transdifferentiation potential of BM-derived hematopoietic cells, 30, 31 our data support transdifferentiation as a viable mechanism for lymphvasculogenesis from BM cells. In fact, the prevalent view that terminally differentiated cells do not change their phenotype has been challenged. [15] [16] [17] 32, 33 B lymphocytes can become macrophage-like cells on overexpression of the C/EBP transcription factor. 34 Fully differentiated somatic cells can be reprogrammed into pluripotent stem cells with ectopic expression of pluripotency-related transcription factors. 35 A battery of 3 transcription factors was able to convert differentiated exocrine cells into functional ␤-cells in adult mice. 36 Conditional inactivation of Prox1 in adult mice induced cell fate change from LECs into blood endothelial cells, 25 suggesting plasticity of differentiated cells. Our data also showed that BM-derived pod ϩ cells clearly express PROX-1 and could become LECs in pathological conditions. To determine the contribution of injected pod ϩ cells to LECs, we used comprehensive and multimodal approaches. Both freshly isolated and culture-isolated pod ϩ cells were used as cell sources. For cell tracking in vivo, both DiI-labeled and GFP-mice-derived cells were used. As in vivo models, we used various animal models such as tumor, inflammation, and wound models, which represent the most prevalent clinical conditions associated with lymphatic vascular growth. The fact that pod ϩ cells gave rise to LECs in all these models supports the identity of pod ϩ cells as LEPCs. To prove this transdifferentiation, we used both static and in vivo confocal microscopy technologies and adopted rigorous criteria as follows. As criteria for transdifferentiation, we required not only the incorporation of injected cells into lymphatic vessels but also exact colocalization of injected cells showing single nuclei with LEC marker staining at 2 different orthogonal images and at multiple Z-stacked files. To further confirm this colocalization, 3-dimensional reconstructions were used. In addition, for identification of lymphatic vessels that harbor the injected cells, both positive staining for multiple lymphatic markers and clear morphology of the vessels were required. These multiple criteria and high standards ensured that we were seeing true transdifferentiation of injected cells rather than artifacts. Common expression of LYVE-1 in LECs and a subpopulation of monocyte-macrophage lineage increases this likelihood of transdifferentiation as well. 15, 37, 38 Our data indicate that pod ϩ cells also contribute to lymphatic neovascularization through paracrine lymphangiogenic effects on existing lymphatic vessels. Similar evidence for the role of BM-derived cells in postnatal lymphangiogenesis in pathological conditions has been reported. He et al 9 showed that BM-derived GFP ϩ cells were heavily recruited to the periphery of new lymphatic vessels after tumor implantation, although a few were incorporated into lymphatic vessels. In other reports, depletion of macrophages inhibited inflammation-induced new lymphatic vessel formation. 29, 39 Macrophages isolated from mice undergoing extensive lymphangiogenesis displayed a marked increase in lymphangiogenic cytokines. 39, 40 These studies support a specific population of BM-derived cells playing an important role in lymphangiogenesis.
In this study, we demonstrated that BM cells that express pod and CD11b can function as LEPCs. A recent report showed that CD11b ϩ macrophages may play an important role in inflammation-induced lymphvasculogenesis in the cornea. 15 However, this study demonstrated only that tissueresident CD11b ϩ macrophages, which are presumably derived from BM, show an LEC phenotype. In contrast, our study clearly demonstrated that BM hematopoietic cells are the source of lymphvasculogenic CD11b ϩ cells and, using in vitro culture methods and in vivo physiological and pathological conditions, further identified a specific cell population among the heterogeneous CD11b ϩ , ie, pod ϩ CD11b ϩ , cells that can function as LEPCs.
Our study identifies pod ϩ cells as LEPCs and proposes their crucial role in lymphvasculogenesis and lymphangiogenesis. The identification of this phenotype has important clinical significance. A culture isolation protocol has been established, so these cells can be used for treating diseases that can benefit from a lymphatic vascular supply such as lymphedema or wound healing. Furthermore, the quantification of these cells in BM may be used to measure or predict tumor burden, progression, or metastasis, allowing their use as a biomarker.
